1. Introduction {#sec1}
===============

With 1.7 million new patients diagnosed each year, breast cancer becomes a worldwide public health dilemma \[[@bib1]\]. Advanced breast cancer (ABC) comprises both locally advanced and de novo metastatic or recurrent breast cancer. About 6%--10% of breast cancer patients are diagnosed with de novo stage IV disease, and over 30% patients with non-metastatic breast cancer will relapse \[[@bib2]\].

Most ABC is incurable, with a median overall survival (OS) of only two to three years \[[@bib3]\]. The outcome of ABC patients is associated with different prognostic factors, including biological breast cancer subtype, performance status, age, distant metastasis sites, prior therapy and metastatic-free interval (MFI) \[[@bib4], [@bib5], [@bib6]\]. These prognostic factors may influence the therapeutic strategy and the fully evaluation of individual characteristics may be beneficial when making a personalized choice of treatment. As already reported, several prognostic prediction models have been constructed and widely accepted for early-stage breast cancer \[[@bib7], [@bib8], [@bib9], [@bib10], [@bib11]\]. In contrast, until now, only few prognostic models predicting survival of metastatic breast cancer patients have been established \[[@bib12],[@bib13]\], and have not yet been widely validated.

In this study, we searched the data from the China National Cancer Center to investigate the risk factors of survival in ABC patients. Furthermore, we intended to construct and externally validate a nomogram with helpful clinicopathological features for survival prediction of breast cancer patients after metastasis or recurrence.

2. Methods {#sec2}
==========

2.1. Study population {#sec2.1}
---------------------

A total of 2263 female patients diagnosed with breast cancer during 1987 and 2019 who had developed ABC afterwards and were treated in the China National Cancer Center over a period of more than 15 years (from January 2003 to June 2019) were enrolled in our study. The inclusion criteria were as follows: (1) breast cancer confirmed by pathology; (2) female patients with ABC, including metastatic or locoregional recurrent breast cancer, and locally advanced unresectable disease that had relapsed; (3) complete medical information including age at initial diagnosis and relapse, estrogen receptor (ER) status, progesterone receptor (PR) status, human epidermal growth factor receptor 2 (HER2) status, distant metastasis sites, local therapy, first-line therapy. Exclusion criteria included: (1) with previous or coexisting cancers except breast cancer; (2) follow-up less than 1 month from the initiate of first-line therapy. All participants were followed up to June 30, 2019 or date of deaths by outpatient visits or telephone follow-up. Seventy-five percent of included patients were randomized as the training group to identify the prognostic factors and to establish the nomogram for prognostic prediction. The rest of the population were selected as the validation group for evaluation of the nomogram.

2.2. Clinical data {#sec2.2}
------------------

The following clinical data were collected for every patient from medical records: age at diagnosis with ABC, Eastern Cooperative Oncology Group (ECOG) score at diagnosis with ABC, pathological type of primary tumor, the initial T-stage, N-stage and M-stage, breast cancer subtype of primary tumor, metastatic sites (distant lymph node \[DLN\]/liver/lung/bone/brain) or locoregional recurrence, local therapy in first-line treatment (including surgery, radiation, radiofrequency ablation and interventional therapy), first-line therapy, best efficacy of first-line therapy (progressive disease \[PD\], or no PD), MFI, survival month, and overall survival status. Breast cancer subtypes were classified as: (1) luminal-like subtype (ER/PR+ and HER2+/−), (2) HER2 subtype (ER-, PR- and HER2+), (3) triple-negative subtype (ER-, PR- and HER2-). Hormone receptor status was assessed by routine immunohistochemistry (IHC) and HER2 was determined by either IHC or fluorescent in-situs hybridization (FISH). Cancers with 1%--100% ER IHC staining were considered ER-positive and cancers with 1%--100% PR IHC staining were considered PR-positive. HER2 IHC3+ or gene amplified by FISH were regarded as HER2-positive. DLN was considered as non-regional lymph node for breast cancer. The clinical stages were classified based on the 8th American Joint Committee on Cancer (AJCC) TNM staging system. Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 was used to evaluate treatment responses. MFI was measured as time between initial breast cancer and diagnosis of recurrence or metastasis.

2.3. Statistical analysis {#sec2.3}
-------------------------

OS was defined as the time between the cancer metastasis or recurrence and death due to any causes or last follow-up. The cumulative OS was estimated using Kaplan-Meier (KM) analysis. Variables significant at *P* \< 0.05 level in the univariate analysis were incorporated into the Cox multivariate regression analysis. A prediction nomogram was developed based on the independent risk features identified by the cox multivariate regression analysis. The discrimination power of the nomogram was evaluated by the Harrell's concordance index (C-index) with a 95% confidence interval (CI). The nomogram was applied to the validation set for external validation. The predicted survival was compared with the actual condition by calibration plots in both the training and validation cohorts. SPSS (version 19.0, Chicago, IL, USA) and R software (version 3.6.1) with the survival and *rms* package were used for statistical analysis. A two-sided *P* value \< 0.05 was considered significantly different.

3. Results {#sec3}
==========

3.1. Patient characteristics {#sec3.1}
----------------------------

A total of 2263 (56.0%) ABC participants were included in this study. [Fig. 1](#fig1){ref-type="fig"} showed the specific screening process. [Table 1](#tbl1){ref-type="table"} listed the clinicopathological features of patients in the training (n = 1706) and validation sets (n = 557). The median age of the study population was 49.0 (range 20.0--83.0) years old and 1158 (51.2%) patients were younger than 50. The median follow-up was 61.6 months and 1210 (53.5%) patients were dead at the end of the follow-up period. With a median OS of 45.4 months, the 2-year and 3-year OS rates were 75.2% and 60.2%, respectively. Three hundred and forty-three (15.2%) patients presented with de novo stage IV breast cancer. Of the whole population, 362 (16.0%) had MFI no less than 5 years. There were 915 (40.4%), 550 (24.3%), 809 (35.7%), 93 (4.1%), 861 (38.0%), 575 (25.4%) patients having DLN, liver, lung, brain, bone metastasis and locoregional recurrence, respectively. Besides, 47.8% (1082) of the enrolled patients had multi-metastatic sites when first diagnosed with stage IV breast cancer. Luminal-like subtype, HER2 subtype and triple-negative subtype comprised 68.3% (1545), 13.2% (300) and 18.5% (418) of total participants, respectively. Local therapy was performed in 42.0% (951) of patients. During the first-line therapy, 111 (4.9%), 1933 (85.4%) and 219 (9.7%) patients were treated with single-agent chemotherapy, combination therapy and endocrine therapy, respectively. As for patients with HER2-positive (n = 665), 44.5% (296) of them received anti-HER2 therapy in first-line treatment. Two hundred and seventy-five (12.2%) patients had PD when they were first evaluated for the first-line therapy.Fig. 1**Flow diagram of enrolled participants.** ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; ABC, advanced breast cancer.Fig. 1Table 1Clinicopathological features of patients in the training and validation cohorts.Table 1CharacteristicTraining cohort, N (%)Validation cohort, N (%)Age\<50873 (51.17)285 (51.17)≥50833 (48.83)272 (48.83)ECOG0404 (23.68)153 (27.47)11230 (72.10)386 (69.30)272 (4.22)18 (3.23)Pathological typeIDC1577 (92.44)513 (92.10)ILC69 (4.04)17 (3.05)Others60 (3.52)27 (4.85)T-stageT1437 (25.62)132 (23.70)T2714 (41.85)244 (43.81)T3119 (6.98)45 (8.08)T485 (4.98)24 (4.31)Tx351 (20.57)112 (20.11)N-stageN0464 (27.20)157 (28.19)N1431 (25.26)126 (22.62)N2310 (18.17)100 (17.95)N3334 (19.58)112 (20.11)Nx167 (9.79)62 (11.13)M-stageM01452 (85.11)468 (84.02)M1254 (14.89)89 (15.98)SubtypeLuminal-like1160 (68.00)385 (69.12)HER2219 (12.84)81 (14.54)Triple-negative327 (19.17)91 (16.34)DLN metastasisNo1023 (59.96)325 (58.35)Yes683 (40.04)232 (41.65)Liver metastasisNo1302 (76.32)411 (73.79)Yes404 (23.68)146 (26.21)Lung metastasisNo1106 (64.83)348 (62.48)Yes600 (35.17)209 (37.52)Brain metastasisNo1634 (95.78)536 (96.23)Yes72 (4.22)21 (3.77)Bone metastasisNo1063 (62.31)339 (60.86)Yes643 (37.69)218 (39.14)Locoregional recurrenceNo1273 (74.62)415 (74.51)Yes433 (25.38)142 (25.49)Local therapyNo971 (56.92)341 (61.22)Yes735 (43.08)216 (38.78)First-line therapySingle-agent chemotherapy83 (4.87)28 (5.03)Combination therapy1462 (85.70)471 (84.56)Endocrine therapy161 (9.44)58 (10.41)Best efficacy of first-line therapyNo PD1506 (88.28)482 (86.54)PD200 (11.72)75 (13.46)MFI\<5 years1431 (83.88)470 (84.38)≥5 years275 (16.12)87 (15.62)[^1]

3.2. Selected prognostic factors for OS {#sec3.2}
---------------------------------------

After univariable analysis, the variables of pathological type, M-stage, bone metastasis were not related to survival, and were excluded from further analysis ([Table 2](#tbl2){ref-type="table"}). In univariable analysis, some subgroup of patients had similar OS, which were therefore combined as one group in the multivariable analysis, including T1 and Tx, T3 and T4, N0, N1 and Nx, N2 and N3. The multivariable analysis demonstrated that age, ECOG, T-stage, N-stage, subtype, the presence of DLN/liver/brain metastasis, local therapy, best efficacy of first-line therapy and MFI were independent prognostic factors for OS ([Table 2](#tbl2){ref-type="table"}).Table 2Univariable and multivariable cox regression analyses of overall survival in the training cohort.Table 2Univariable analysisMultivariable analysisCharacteristicHR (95% CI)*P* valueCharacteristicHR (95% CI)*P* valueAgeAge\<50Reference\<50Reference≥501.24 (1.09, 1.41)0.0014≥501.21 (1.06, 1.38)0.0048ECOGECOG0Reference0Reference11.40 (1.17, 1.66)0.000211.29 (1.08, 1.54)0.004422.87 (2.11, 3.88)\<0.000122.11 (1.54, 2.87)\<0.0001Pathological typeIDCReferenceILC1.06 (0.78, 1.45)0.7121Others0.74 (0.52, 1.06)0.1020T-stageT-stageT1ReferenceT1/TxReferenceT21.28 (1.09, 1.52)0.0033T21.12 (0.97, 1.29)0.1362T31.92 (1.48, 2.49)\<0.0001T3/T41.32 (1.07, 1.63)0.0096T41.90 (1.42, 2.55)\<0.0001Tx1.10 (0.90, 1.34)0.3381N-stageN-stageN0ReferenceN0/N1/NxReferenceN11.18 (0.98, 1.42)0.0866N2/N31.32 (1.14, 1.52)0.0001N21.59 (1.30, 1.93)\<0.0001N31.87 (1.55, 2.27)\<0.0001Nx1.25 (0.98, 1.61)0.0737M-stageM0ReferenceM11.14 (0.95, 1.37)0.1719SubtypeSubtypeLuminal-likeReferenceLuminal-likeReferenceHER21.48 (1.22, 1.80)\<0.0001HER21.21 (0.99, 1.48)0.0597Triple-negative1.64 (1.39, 1.93)\<0.0001Triple-negative1.64 (1.38, 1.95)\<0.0001DLN metastasisDLN metastasisNoReferenceNoReferenceYes1.60 (1.40, 1.82)\<0.0001Yes1.50 (1.30, 1.72)\<0.0001Liver metastasisLiver metastasisNoReferenceNoReferenceYes1.84 (1.59, 2.13)\<0.0001Yes1.74 (1.49, 2.04)\<0.0001Lung metastasisLung metastasisNoReferenceNoReferenceYes1.22 (1.07, 1.40)0.0035Yes0.97 (0.84, 1.13)0.7079Brain metastasisBrain metastasisNoReferenceNoReferenceYes2.04 (1.52, 2.73)\<0.0001Yes2.53 (1.85, 3.46)\<0.0001Bone metastasisNoReferenceYes1.12 (0.98, 1.28)0.0872Locoregional recurrenceLocoregional recurrenceNoReferenceNoReferenceYes0.72 (0.62, 0.84)\<0.0001Yes1.03 (0.87, 1.21)0.7284Local therapyLocal therapyNoReferenceNoReferenceYes0.55 (0.48, 0.63)\<0.0001Yes0.60 (0.52, 0.70)\<0.0001First-line therapyFirst-line therapySingle-agent chemotherapyReferenceSingle-agent chemotherapyReferenceCombination therapy1.40 (1.17, 1.66)0.0002Combination therapy0.76 (0.57, 1.02)0.0631Endocrine therapy2.87 (2.11, 3.88)\<0.0001Endocrine therapy0.69 (0.48, 1.00)0.0475Best efficacy of first-line therapyBest efficacy of first-line therapyNo PDReferenceNo PDReferencePD2.05 (1.69, 2.47)\<0.0001PD2.05 (1.69, 2.50)\<0.0001MFIMFI\<5 yearsReference\<5 yearsReference≥5 years0.62 (0.51, 0.75)\<0.0001≥5 years0.75 (0.61, 0.92)0.0062[^2]

3.3. Prognostic nomogram for OS {#sec3.3}
-------------------------------

The positive variables in multivariable analysis were integrated into the nomogram scoring system ([Fig. 2](#fig2){ref-type="fig"}). The value of each of these variables was given a score on the point scale axis. The estimated probability of 2-year and 3-year OS was calculated by counting the scores and locating on the total point scale. The C-indexes of the nomogram were 0.700 (95% CI: 0.683--0.717) and 0.686 (95% CI: 0.652--0.719) for the training and the validation sets, respectively. The calibration plots revealed satisfactory agreement between actual survival and predicted survival in both the internal ([Fig. 3](#fig3){ref-type="fig"}) and external validations ([Fig. 4](#fig4){ref-type="fig"}).Fig. 2**Nomogram for predicting the 2-year and 3-year overall survival.** ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor receptor 2; DLN, distant lymph node; PD, progressive disease; MFI, metastatic-free interval.Fig. 2Fig. 3The calibration curve to predict 2-year and 3-year overall survival (OS) in the training cohort.Fig. 3Fig. 4The calibration curve to predict 2-year and 3-year overall survival (OS) in the validation cohort.Fig. 4

3.4. Risk stratifications using the new nomogram {#sec3.4}
------------------------------------------------

We categorized patients with similar outcome in the training set into three subgroups based on the predicted probability of 3-year OS: low-risk (\>0.70), medium-risk (0.40--0.70) and high-risk groups (0--0.40). Three subgroups of the whole population had significant difference among the KM curves ([Fig. 5](#fig5){ref-type="fig"}, all *P* \< 0.0001). The low-risk, medium-risk and high-risk subgroups had 84.9%, 55.1% and 27.6% 2-year OS, and 71.3%, 35.8% and 8.4% 3-year OS, respectively. The median OS of patients with low, medium and high risk were 57.0, 26.7 and 16.3 months. In patients with liver metastasis, the low-risk, medium-risk and high-risk subgroups had 78.4%, 53.5% and 28.1% 2-year OS, and 68.3%, 32.6% and 13.0% 3-year OS, respectively ([Fig. 6](#fig6){ref-type="fig"}, all *P* \< 0.0001). Similarly, in patients with triple-negative disease, the low-risk, medium-risk and high-risk subgroups had 72.7%, 55.3% and 24.1% 2-year OS, and 59.0%, 36.8% and 5.4% 3-year OS, respectively ([Fig. 7](#fig7){ref-type="fig"}, all *P* \< 0.0001).Fig. 5Survival probability of nomogram-based stratification of overall population.Fig. 5Fig. 6Survival probability of nomogram-based stratification of patients with liver metastasis.Fig. 6Fig. 7Survival probability of nomogram-based stratification of patients with triple-negative disease.Fig. 7

4. Discussion {#sec4}
=============

Without a widely accepted consensus on medical treatment, ABC remains incurable \[[@bib6]\]. Prognosis of patients with ABC varies greatly on an individual level, even survival times of up to 15 years have been reported \[[@bib14]\]. A valid prediction tool to identify ABC patients with promising prognostic factors can help clinicians make more appropriate clinical decisions. However, only limited numbers of prediction models used in advanced/metastatic breast cancer have been reported until now \[[@bib12],[@bib15]\]. Li et al. \[[@bib12]\] developed a model to predict the prognosis of stage IV breast cancer patients based on the data from the National Cancer Database in the United states, but they failed to distinguish the de novo metastatic patients from those who progressed to metastatic diseases after adjuvant treatments. Lee et al. \[[@bib15]\] established a nomogram, with a C-index of 0.65 (95%CI: 0.62--0.67), developed from ABC patients administrated with anthracyclines, cyclophosphamide, or capecitabine as first-line chemotherapy, which might be restricted for widely use in patients accepting other treatments including effective cytotoxic agents, endocrine and targeted therapies \[[@bib16], [@bib17], [@bib18], [@bib19]\]. In our study, we have established a prediction model based on widely available baseline clinicopathological features to predict survival for patients with ABC using data from our center.

One interesting thing we have found was that the initial tumor size and primary axillary lymph node status were related to the survival after relapse, which was consistent with the previous studies \[[@bib20],[@bib21]\]. We should not neglect the fact that there was a relatively high proportion of patients with unknown T-stage (Tx = 20.57%) and unknown N-stage (Nx = 9.79%), which suggested the results needed further confirmation. The other thing we have found was that there was no significant difference in outcome between de novo and relapsed metastatic breast cancer in our data (M1 vs M0, HR = 1.14, 95% CI = 0.95--1.37, *P* = 0.1719). The prognosis of patients with de novo stage IV breast cancer was reported to be superior compared with those with recurrent diseases \[[@bib2],[@bib22]\], likely due to the single metastatic site, hormone receptor positive with single bone metastasis, treatment naïve and trastuzumab treatment for HER2+ disease. However, other studies found no difference in outcome between these two cohorts \[[@bib23],[@bib24]\], which were in accord with our study. The increased efficacy of new agents and the various metastatic sites might have smoothened the possible overall survival difference. Some researchers demonstrated that the different outcomes between these two cohorts of patients depended on the MFI \[[@bib2],[@bib25]\]. Compared with de novo stage IV breast cancer patients, relapsed breast cancer patients with longer MFI had similar risk of death. In conclusion, it seemed that the reasons behind the survival distinctions between women with de novo and recurrent metastatic breast cancer came to the different clinicopathological features, including breast cancer subtype, metastatic sites, efficacy of the systemic treatment and MFI. Therefore, we included de novo stage IV breast cancer patients in the study population to build the prediction model, unlike the other studies \[[@bib15],[@bib21]\] which had excluded patients with distant metastasis at initial diagnosis. We analyzed the features including breast cancer subtype, metastatic sites, efficacy of the systematic treatment and MFI and the multivariate analysis proved that they were positive prognostic factors for OS.

Based on the stratification analysis, the developed nomogram could be applied to identifying patients with different risks. Breast cancer patients with liver metastasis were reported to have an unfavorable prognosis, with a median post-metastasis survival of approximately 18--24 months \[[@bib26]\]. Effective local therapy of breast cancer liver metastasis achieved a survival advantage over adequate systemic therapy in a special group of patients \[[@bib27]\]. However, how to choose patients with favorable prognostic factors and suitable for the local treatment remained uncertain. This prediction model could identify low-risk patients who might benefit from aggressive local curative treatment of liver metastasis. As for advanced patients with aggressive triple-negative breast cancer (TNBC), treatment remained challenging. The prediction model suggested that the low-risk group of TNBC patients could have relatively better outcome. More intensive attempts, including atezolizumab plus nab-paclitaxel \[[@bib28]\] and olaparib \[[@bib29]\], were supposed to be recommended for this group of patients to achieve clinical remission. The ability to identify patients with high risk was essential in making personal decisions for the remaining lifetime in addition to the treatment options, since the therapies might not only be less beneficial but also increase unnecessary compromise in quality of life.

There were several limitations of the current study. Firstly, less record of the metastatic tumor receptor status was one of the deficiencies of the model, since phenotype discordance has been found between primary and relapsed breast cancer \[[@bib30]\]. Reassessment of the HER2 and hormone receptor expression profile at the time of disease relapse might optimize the prognostic model. Secondly, we need different population from another center to externally validate this prediction model. Finally, the missing clinical data and loss to follow-up of the patients might have some effects on the discriminatory and predictive capacities of the nomogram. We are supposed to design a prospective trial to further validate the model in the future.

5. Conclusions {#sec5}
==============

In summary, we demonstrated important risk factors in ABC patients and incorporated these parameters into a nomogram to predict the outcome of the patients. This prognostic model could help patients better understand their future prognosis and could also guide the physicians to make personalized therapeutic decisions for individual ABC patients.
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[^1]: ECOG Eastern Cooperative Oncology Group, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, HER2 human epidermal growth factor receptor 2, DLN distant lymph node, PD progressive disease, MFI metastatic-free interval.

[^2]: HR hazard ratio, CI confidence interval, ECOG Eastern Cooperative Oncology Group, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, HER2 human epidermal growth factor receptor 2, DLN distant lymph node, PD progressive disease, MFI metastatic-free interval.
